GenFleet interim loss narrows to RMB 220.17 million in FY26 H1; revenue falls to RMB 42.47 million

• GenFleet Therapeutics posted a net loss of RMB 220.17 million for the six months ended June 30, 2026, narrowing from RMB 698.6 million.
• Revenue fell to RMB 42.47 million from RMB 88.74 million, reflecting a RMB 71.17 million drop in IP licensing.
• R&D expenses climbed to RMB 192.53 million from RMB 122.44 million, driven by more pipelines and higher investment in existing programs.
• Other income and gains rose to RMB 40.62 million from RMB 8.18 million, on higher time-deposit interest income.
• Cash and bank balances totaled RMB 1.78 billion at June 30, 2026, down from RMB 2.07 billion at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293612), on August 21, 2026, and is solely responsible for the information contained therein.